Jonathan Kimmelman

Jonathan_Kimmelman

Theme Leader
Jonathan Kimmelman, PhD
Associate Professor
Biomedical Ethics/Social Studies of Medicine/Dept. Human Genetics
McGill University
3647 Peel St
Montreal, Quebec, Canada H3A 1X1
jonathan.kimmelman@mcgill.ca
Phone:+514-398-3306
Fax: +514-398-8349
www.mcgill.ca/biomedicalethicsunit/faculty/kimmelman/
www.translationalethics.com/
Group for Studies of Translation, Ethics, and Medicine (Stream)

Jonathan Kimmelman is Associate Professor in the Biomedical Ethics Unit at McGill, with cross appointments in Epidemiology and Biostatistics and Experimental Medicine. His research centers on ethical and policy issues surrounding therapeutic development, with a particular focus on risk, uncertainty, decision-making and evidence production.  His also serves in various advisory capacities, including chair of the ethics committee of the International Society of Stem Cell Research. Kimmelman holds a PhD in Molecular Biophysics and Biochemistry.

 

About Jonathan’s Team

Post-Doctoral Fellow
Spencer Phillips Hey, PhD
heyspencer@gmail.com

Spencer Phillips Hey is a postdoctoral fellow working with Jonathan Kimmelman in the Biomedical Ethics Unit at McGill University. He received his PhD in Philosophy in 2011 from Western University. He obtained his BA (Hons) in Philosophy from University of Illinois at Chicago in 2004. His research interests include philosophy of science and research ethics. His work on the ethics and methodology of clinical trials has appeared in Science Translational Medicine, Trials, and Perspectives in Biology and Medicine.

Research Assistant
Georgina Freeman, MSc
georgina.freeman@mail.mcgill.ca

Georgina Freeman is a graduate of the Biomedical Ethics Master’s program at McGill. Her thesis explored ethical justifications of research biopsies for pharmacodynamic study in early phase cancer trials. This work produced two articles published in the British Journal of Cancer and Clinical Cancer Research. Her current project aims to characterize the development of predictive biomarkers tied to cancer therapeutics.